On September 19, 2023, Precision BioSciences (NASDAQ: DTIL) received a Buy rating from HC Wainwright & Co. analyst Patrick Trucchio, who maintained a price target of $3. This positive rating contrasts with the company’s average rating of outperform and price targets ranging from $1 to $5, as reported by analysts polled by Capital.
As of August 2, 2023, the average one-year price target for Precision BioSciences stood at $3.26, with forecasts ranging from a low of $1.01 to a high of $5.25.
Despite the optimistic outlook from HC Wainwright & Co., four stock analysts predict a lower average 12-month stock price forecast for DTIL stock at $2.50. However, this still anticipates a significant increase of 495.52%.
Furthermore, the average portfolio weight of all funds dedicated to DTIL is 0.07%, indicating a decrease of 20.43% in average portfolio weight. Institutions also experienced a decline of 18.87% in total shares owned.
Overall, these statistics provide a mixed perspective on Precision BioSciences’ future performance in the stock market.
Precision BioSciences, Inc.
Updated on: 03/10/2023
Debt to equity ratio: Strong Buy
Price to earnings ratio: Sell
Price to book ratio: Strong Buy
DCF: Strong Buy
ROE: Strong Sell
2:00 AM (UTC)
Date:03 October, 2023
|Analyst / firm||Rating|
Precision BioSciences, Inc. (DTIL) Stock Performance Analysis: September 19, 2023
On September 19, 2023, the stock performance of Precision BioSciences, Inc. (DTIL) was closely monitored by investors and analysts. The stock had a previous close of $0.42 and opened at the same price. Throughout the day, the stock traded within a range of $0.41 to $0.43. The total volume of shares traded was 6,236, which was significantly lower than the average volume of 994,242 shares over the past three months.
DTIL has a market capitalization of $48.5 million. The company’s earnings growth for the current year is positive at +25.59%. No information is available regarding the earnings growth for the next five years.
The revenue growth for DTIL in the previous year was -78.28%. The price-to-sales ratio for DTIL is 4.17, which indicates that investors are willing to pay a premium for each dollar of sales generated by the company. The price-to-book ratio is 0.77.
In terms of today’s stock performance, DTIL experienced a decrease of $0.03 or -2.42%. Other stocks in the sector and industry also experienced mixed performance, with Quince Therapeutics and ImmuCell Corp witnessing declines, while Aslan Pharmaceuticals saw an increase in stock price.
Precision BioSciences, Inc. is a health technology company operating in the biotechnology industry. It is headquartered in Durham, North Carolina. The company specializes in gene editing technologies and develops therapies for various diseases.
Investors and analysts will be closely monitoring DTIL’s next reporting date on November 14, 2023. The company is expected to report an earnings per share (EPS) forecast of -$0.24 for the current quarter. In the previous year, DTIL generated annual revenue of $25.1 million but reported a net loss of -$111.6 million, resulting in a negative net profit margin of -444.80%.
In conclusion, DTIL’s stock performance on September 19, 2023, showed a decline of -2.42%. Investors should carefully consider the risks associated with investing in a small biotechnology company like DTIL and stay updated on the company’s financial performance and industry trends.
DTIL Stock Analysis: Promising Future and Potential Growth
DTIL stock, representing Precision BioSciences Inc, had an interesting performance on September 19, 2023. According to data from CNN Money, the 5 analysts offering 12-month price forecasts for DTIL have a median target of $3.00, with a high estimate of $4.00 and a low estimate of $1.40. This indicates a potential increase of 608.72% from the last recorded price of $0.42.
The fact that the median estimate suggests such a significant increase in DTIL’s stock price is certainly noteworthy. It indicates that analysts have a positive outlook on the company’s future performance and potential for growth. This sentiment is further supported by the current consensus among 5 polled investment analysts, who all recommend buying DTIL stock. This rating has remained steady since September, indicating that analysts have maintained their positive stance on the company’s prospects.
It is important to note that the current quarter’s earnings per share for DTIL stand at -$0.24, which means that the company is currently reporting a loss. However, it is worth considering that the stock’s potential for growth, as indicated by the analysts’ forecasts, may be based on factors beyond the current quarter’s financial performance. Investors may be looking at the company’s long-term potential, such as its pipeline of products or its position in the market, to justify their optimistic outlook.
In terms of sales, DTIL reported $7.0 million for the current quarter. While this figure may not be exceptionally high, it is important to consider the company’s growth trajectory and potential for future revenue generation. As a biotechnology company, Precision BioSciences Inc may be investing heavily in research and development, which could impact its current financials. Investors and analysts may be looking at the company’s sales figures in the context of its overall strategy and potential for future success.
It is worth noting that DTIL’s next reporting date is scheduled for November 14. This will provide investors with more insights into the company’s financial performance and may impact the stock’s future trajectory. Market participants should keep an eye on this date and any subsequent announcements or updates from Precision BioSciences Inc.
In conclusion, DTIL stock had a notable performance on September 19, 2023, with analysts predicting a significant increase in its price. While the company is currently reporting a loss and its sales figures may not be exceptional, investors and analysts seem to be focusing on its long-term potential and growth prospects. The upcoming reporting date on November 14 will provide further clarity on DTIL’s financial performance and may shape the stock’s future trajectory.